Adaptive radiation therapy for localized prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a type of radiation that adapts to your body's changes during treatment. It is for men with low- to intermediate-risk prostate cancer that hasn't spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 or older with prostate cancer that is low or intermediate risk according to national guidelines
- You have not had prior treatment like radiation, surgery, freezing, or ultrasound for this cancer
- You have not had any procedures to open up the bladder outlet, such as TURP or HoLEP
- Your prostate is not larger than about 80 cubic centimeters on MRI and your urinary symptom score is 17 or lower
- You weigh 200 kilograms or less and are not allergic to polyethylene glycol or iodine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precise radiation technique that adapts to your body's daily changes. It may offer better outcomes for men with prostate cancer that hasn't spread outside the pelvic area.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
This trial tests whether a special type of radiation therapy, guided by MRI, can treat prostate cancer with fewer side effects. The treatment is given in a highly precise way to target the cancer while sparing healthy tissue.
This trial studies a combination of two radiation types—high-dose-rate brachytherapy and stereotactic body radiotherapy—to treat certain intermediate- to high-risk prostate cancers. It may help by aiming radiation closely at the prostate while also targeting the cancer from outside the body.
This trial tests a new way to deliver high-precision radiation to the prostate using daily MRI or CT scans to adjust the treatment based on your exact anatomy. It aims to make radiation more accurate and reduce side effects.
Hear when a new Localized Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.